GFRA1: GDNF family receptor alpha-1
Coreceptor for GDNF, a neurotrophic factor that enhances survival and morphological differentiation of dopaminergic neurons and increases their high-affinity dopamine uptake.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on GFRA1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 1
| CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS | Liatermin | Phase 1 | Active, not recruiting | Cedars-Sinai Medical Center | Apr 1, 2022 |
| GDNF Gene Therapy for Multiple System Atrophy | Liatermin | Phase 1 | Active, not recruiting | Brain Neurotherapy Bio, Inc. | Dec 22, 2020 |
| GDNF Gene Therapy for Parkinson's Disease | Liatermin | Phase 1 | Active, not recruiting | Brain Neurotherapy Bio, Inc. | Nov 19, 2019 |
- Renal hypodysplasia/aplasia 40.47
- Renal agenesis0.38
- Bilateral renal agenesis0.37
- Smoking initiation0.36
- Bone Paget disease0.31
- Hirschsprung disease0.26
- Contracture0.24
- Bile duct disorder0.24
- Stroke disorder0.23
- Alcohol drinking0.23
- Neurodegenerative disease0.19
- Ulcerative colitis0.18
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3833481, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P56159, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets